[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-node\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-node":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,74,130,156,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100462840","molecular-analysis-of-endoscopic-cytology-samples-supernatant-in-pulmonary-nodules-100462840",false,"NCT05306912","Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules","Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules (Cancer Or Benign Endoscopy) (KOBE)","KOBE","Inclusion Criteria:\n\n* rEBUS bronchoscopy planned for one, two or three ≤ 20 mm nodule\n* World Health Organization (WHO) Performance status 0-3\n* Informed signed consent\n* Patient affiliated or beneficiary of a social security scheme (Social Security or Universal Medical Coverage).\n\nExclusion Criteria:\n\n* Lung cancer diagnosed before the date of the procedure\n* Lung cancer strongly suspected due to mediastinal or extra thoracic lesions\n* Patient under State Medical Assistance\n* Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Lung cancer screening is based on low dose CT scan (LDCT), a highly sensitive but poorly specific tool.\n\nComplementary specific approaches are thus strongly needed, among which cell-free DNA (cfDNA) genotyping has been proven highly specific but of low sensitivity (25 to 50% for stage I diseases) due to inconstant tumor shed. Tumor biopsy is thus often required and radial endobronchial ultrasound (rEBUS) bronchoscopy is a minimally invasive approach (\\\u003C3% complications) but of limited sensitivity in cases of nodules \\\u003C 20 mm.\n\nThe investigators hypothesized that methylation analysis on cfDNA floating in supernatant derived from rEBUS specimens could improve rEBUS sensitivity",[27,28],"Lung Cancer","Lung; Node",[30,31,32,33,34,35,36],"Circulating free DNA","Methylation","Lung cancer","screening","lung nodule","radial EBUS","endobronchial ultrasound","RECRUITING","2026-04-28",{"date":40,"type":41},"2026-04-29","ACTUAL",{"date":43,"type":41},"2022-04-08",{"date":45,"type":21},"2026-12",{"name":47,"class":48},"University Hospital, Toulouse","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":49},"100490390","using-biomarkers-for-diagnosis-risk-stratification-of-post--treatment-recurrence-and-long-term-surveillance-of-lung-cancer-100490390","NCT05665504","Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer","Inclusion Criteria:\n\n* Potentially-resectable lung nodule 8-40 mm diameter suspected (no preop diagnosis) of being a clinically node-negative lung cancer \\[clinical stage IA-IB (cT1a-T2aN0), \\\u003C4cm diameter\\].\n* If surgical resection is recommended, patient will undergo surgery at Moffitt Cancer Center.\n* If a definite tissue diagnosis is obtained and stereotactic body radiotherapy (SBRT) is the recommended treatment instead of surgery, the SBRT will be delivered at Moffitt Cancer Center.\n* \\>18 years old, male or female.\n* ECOG performance status 0-1.\n* Agree to participate in the follow-up protocol.\n* Any suspected primary lung cancer cell type (except a suspected typical carcinoid tumor, carcinoma in situ or minimally-invasive carcinoma).\n* Ability to understand and the willingness to sign a written, informed consent document.\n\nExclusion Criteria:\n\n* Participants who are actively receiving any cancer treatment.\n* Participants with uncontrolled intercurrent illness.\n* Prior lung cancer within 5 years.\n* Current active other major cancer except non-melanoma skin cancer.\n* Patients with pure ground glass opacities (nodules) or hilar masses.\n* Suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma).\n* Metastatic nodule (suspected) in the lung from an extrapulmonary cancer.\n* Patient unable to provide informed consent.\n* Prisoner or incarcerated individual.\n* For surgical patients, a R1 or R2 resection.",{"count":57,"type":21},250,"OBSERVATIONAL","This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.",[28,61],"Adenocarcinoma of Lung",[63,64],"Biomarkers","Lung Cancer Biomarkers","2026-03-31",{"date":67,"type":41},"2026-04-01",{"date":69,"type":41},"2023-01-11",{"date":71,"type":21},"2028-02",{"name":73,"class":48},"H. Lee Moffitt Cancer Center and Research Institute",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":58,"phases":4,"briefSummary":85,"conditions":86,"keywords":116,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":49},"100474891","inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer-100474891","NCT05463796","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer","Inclusion Criteria:\n\n* Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type):\n\n  1-Hereditary risk for cancer including\n  * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes\n  * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)\n  * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)\n  * Hereditary Cancer Prediction Model-based elevated cancer risk\n  * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\\&N cancer for example), etc.\n* Exposed High Risk including\n\n  * Childhood cancer survivors with treatment exposures associated with increased risk of cancer\n  * Adult cancer survivors with treatment exposures associated with increased risk of cancer\n  * Documented high level exposure to group 1 IARC carcinogens\n  * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \\>50, Smoking history of \\>15 pack years, First-degree relative history of lung cancer or COPD\n  * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis\n* Precursor Lesions including\n\n  * Breast: ductal\u002Flobular carcinoma in situ (CIS) and atypical hyperplasia\n  * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia\u002Fadenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis\n  * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia\u002Fcarcinoma in situ,\n  * Lung: Adenomatous hyperplasia\n  * H\\&N: high-risk oral precancerous diseases\n  * Skin: Class II melanocytic lesions. Squamous dysplasia\n  * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas\n  * Thoracic: Lung nodules detected on screening CT that prompt further follow-up\n  * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia\n  * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others.\n* FAMILY MEMBERS or healthy individuals\n\nExclusion Criteria:\n\nThere are no exclusion criteria for the study.\n\nNote: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.",true,{"count":83,"type":21},5000,"20 Years","This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.\n\n* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.\n* The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.",[87,88,89,90,91,92,93,27,94,95,96,97,98,99,100,101,102,103,104,105,106,28,107,108,109,110,111,112,113,114,115],"Cancer Risk","Cancer Predisposition Syndrome","Hereditary Cancer Prediction","Childhood Cancer Survivors","Adult Cancer Survivors","IARC Carcinogens","Smoking History","Ductal\u002FLobular Carcinoma","Barrett Esophagus","Pancreatic Precursor Lesions","Colonic Dysplasia\u002FAdenomata","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Steatohepatitis","Cirrhosis","High Grade Prostatic Epithelial Neoplasia","High-grade Bladder Urothelial Dysplasia\u002FCarcinoma in Situ","Adenomatous Hyperplasia","High-risk Oral Precancerous Diseases","Melanocytic Lesion, Adult","Hematologic Malignancy","Serous Tubal Intraepithelial Carcinoma","Endometrial Intraepithelial Neoplasia","Cervical and Endocervical Carcinoma in Situ","Vulvar Intraepithelial Neoplasia","Nephrogenic Rests","Benign Bone Lesions With Risk of Malignant Degeneration","Giant Cell Tumor","Osteochondroma","Spitz Nevus",[117,118,119,120],"Hereditary Risk for Cancer","Childhood cancer survivors","Adult cancer survivors","Precursor Lesions","2025-08-04",{"date":123,"type":41},"2025-08-07",{"date":125,"type":41},"2023-04-25",{"date":127,"type":21},"2032-03-25",{"name":129,"class":48},"Dana-Farber Cancer Institute",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":49},"100566307","development-and-demonstration-of-intelligent-assessment-based-on-multi-modal-information-fusion-for-tumor-risk-and-diagnosis-and-treatment-100566307","NCT06653478","Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment","Inclusion Criteria:\n\n1. Participants with the suspected of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision\n2. Participants that have signed informed consent.\n3. Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.\n4. Healthy participants with no clinical diagnosis of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision.\n\nExclusion Criteria:\n\n1. Participants with primary clinical and pathological data missing.\n2. Participants lost to follow-up.\n3. Participants with too poor medical image quality to perform segment and mark ROI accurately","75 Years",{"count":138,"type":21},3000,"To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.",[141,142,27,28,143,144,87,145,146],"Artificial Intelligence","Deep Learning","Stomach Cancer","Colon Cancer","Cancer Screening","Cancer, Treatment-Related","2024-10-20",{"date":149,"type":41},"2024-10-22",{"date":151,"type":41},"2022-06-01",{"date":153,"type":21},"2026-10-01",{"name":155,"class":48},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":165,"studyType":58,"phases":4,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":49},"100500834","from-benchmark-to-surgical-activity-the-role-of-endobronchial-fiducial-markers-for-ground-glass-lung-nodules-resection-100500834","NCT05801406","From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.","Vortex_US","Inclusion Criteria:\n\n* all patients over the age of 18;\n* lung GGNs with the presence of a solid part inside \\> = 6 mm or with a solid part even less than 6 mm but with an increase in size;\n* subjects evaluated for surgical treatment during multidisciplinary tumor board.\n\nExclusion Criteria:\n\n* Patients not eligible for surgery",{"count":164,"type":21},5,"12 Months","With the risen popularity of low-dose computed tomography (LDCT) for lung cancer screening, many patients present with peripheral pulmonary ground-glass nodules (GGNs) with a suspicious solid part. The appropriate diagnostic and management strategy for those lesions can be questionable. If malignancy is suspected, a surgical biopsy with the guidance of various localization methods available is recommended.\n\nEach localization method has its advantages and disadvantages. Therefore, it may not be possible to establish a gold standard for localizing indeterminate lung nodules since comparative clinical trials are lacking.",[27,168,28],"Lung Non-Small Cell Carcinoma",[170,171,172,173,174,175],"Ultrasound","Marker","Fluoroscopy","Lung","Cancer","Bronchoscopy","NOT_YET_RECRUITING","2024-07-29",{"date":179,"type":41},"2024-07-30",{"date":181,"type":21},"2024-10-01",{"date":183,"type":21},"2025-10-31",{"name":185,"class":48},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":192,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":139,"conditions":193,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":198,"leadSponsor":200,"locationsCount":49},"100471996","artificial-intelligence-system-for-assessment-of-tumor-risk-and-diagnosis-and-treatment-100471996","NCT05426135","Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment","Development of an Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment Based on Multimodal Data Fusion Using Deep Learning Technology",{"count":138,"type":21},[141,142,27,28,143,144,87,145,146],"2022-06-17",{"date":196,"type":41},"2022-06-21",{"date":151,"type":41},{"date":199,"type":21},"2026-10",{"name":155,"class":48}]